ABSTRACT: Chronic wounds including diabetic foot ulcers, pressure ulcers, and venous leg ulcers are a worldwide health problem. As the traditional methods of treatment have proven ineffective against chronic wounds involving biofilms, there is an unmet clinical need for developing products with an antibiofilm component that inhibits and/or disrupts biofilms and thus make the biofilm-embedded bacteria more susceptible to antimicrobial therapy. We developed a DispersinB® antibiofilm enzyme-based wound spray for treating chronic wounds in conjunction with an antimicrobial. Under in vitro conditions, the DispersinB® and Acticoat™ combination performed significantly better (P  0.05) than Acticoat™ alone, indicating the synergy between the two compounds because of DispersinB® enhancing the antimicrobial activity of Acticoat™. Furthermore, DispersinB® wound spray enhanced the antimicrobial activity of Acticoat™ in a chronic wound mouse model of methicillin-resistant Staphylococcus aureus (MRSA) infection. Thus, this novel combination of DispersinB® and Acticoat™, an antimicrobial dressing, prompts clinical evaluation for potential applications in biofilm-based chronic wound management.
Introduction
An epidemic increase in obesity combined with an aging population has caused chronic wounds such as diabetic foot ulcers, pressure ulcers, and venous leg ulcers to become an increasing clinical concern. More than 2% of the US population suffers from chronic, nonhealing wounds 1 and with only transiently effective antimicrobials; the current standard of care is amputation with 24% of diabetic patients undergoing amputation surgery in their lifetime. 2 Although chronic and acute wounds progress through similar stages of healing, chronic wounds appear to stall in the inflammatory stage of wound healing, likely because of persistent colonization by bacteria. 3 Colonization by bacteria contributes to nonhealing of the wound; however, recent evidence suggests that development of a chronic wound is dependent on contaminating bacteria forming biofilms. In chronic wounds, the biofilm mode of growth is characterized by adherence to biotic or abiotic surfaces, slow development of overt symptoms, a lack of resolution by host defenses, and resistance to antibiotic therapy. 4 Furthermore, recent studies by James et al 2 have demonstrated biofilm as a potential reason why chronic wounds do not heal. Adaptation by biofilm communities has resulted in the failure of multiple antimicrobials; thus; synergistically acting combinations of antibiofilm and antimicrobials have the greatest likelihood of remaining efficacious in the clinic. Wolcott and Rhoads 5 observed that the chronic wound treatments that specifically target biofilms transformed nonhealable wounds into healable wounds. When combined with antibiofilm compounds, the use of antibiotics declined approximately 25% during the four-year study period. Thus, the use of suitable topical agents that inhibit biofilm formation or disrupt preformed biofilm should be integral to the management of chronic wound infections.
Dr. George G. Zhanel (Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada). The clinical wound isolates of MRSA Gav 16a and coagulase-negative staphylococci (CoNS) 42 were obtained from Dr. Randolph D. Wolcott (Southwest Regional Wound Care Center, Lubbock, TX, USA). All the strains were maintained at -80°C in 15% (v/v) glycerol stocks and recovered onto tryptic soy agar (TSA) and tryptic soy broth (TSB).
Biofilm assay. To evaluate the effect of DispersinB® wound spray on biofilm inhibition and dispersal, a 96-well biofilm assay was performed. 8 For biofilm inhibition assay, the overnight grown cultures were diluted 100 times in TSB medium and grown in a 96-well microtiter plate in the presence or absence of DispersinB® wound spray for 18 hours at 37°C. For biofilm dispersal assay, cultures were grown in 96-well microtiter plates for 18 hours at 37°C and treated with or without DispersinB wound spray for 3 hours at 37°C. Biofilm was washed and stained with crystal violet, and the absorbance was measured at 630 nm.
Antibiofilm-antimicrobial activity. The MRSA biofilm was developed in a 12-well microtiter plate for 18 hours at 37°C and treated with Acticoat™ alone and in combination with DispersinB® wound spray for three hours at 37°C. 16 The biofilms were washed and suspended in 2 mL phosphate buffered saline (PBS). The plate was sonicated for 30 seconds, and the suspension was transferred into 15 mL tubes. After vortexing the tubes for one minute, serial dilutions were plated onto TSA.
In vivo efficacy. The efficacy of the combination of Acticoat™ and DispersinB® wound spray was studied using a chronic wound mouse model of MRSA infection.
17 A 1.5 cm 2 surgical excision wound was created on the back of 27 mice and an OPSITE dressing was applied over the wound. The wounds were infected with 10 4 CFU of S. aureus. After 24 hours of post-infection, mice were divided into three groups of nine mice each and treated with either placebo (50 mM phosphate buffer + 100 mM NaCl, pH 5.9) or 1.5 cm 2 Acticoat™ alone or a combination of DispersinB® wound spray and Acticoat™. At day 2 of post-wound infection, mice were euthanized, wound sections were harvested, and serial dilutions were plated onto TSA to determine the CFU per gram of tissue. The bacterial load was compared between different groups by using one-way analysis of variance (ANOVA).
Results
DispersinB® wound spray was effective in inhibiting and dispersing biofilms without affecting the growth of woundassociated pathogens such as S. aureus, S. epidermidis, CoNS-42, A. baumannii, and K. pneumoniae (Figs. 1a and b) .
In addition, MRSA biofilm was treated with Acticoat™ alone and in combination with DispersinB® wound spray using a 12-well biofilm assay.
Although biofilm treated with Acticoat™ alone showed 0.4log 10 more bacteria compared to control, the difference was not significant (P  0.05) (Fig. 2) . The combination showed
We have developed a DispersinB® antibiofilm enzymebased wound spray for treating chronic wounds that could be used in conjunction with an antimicrobial. Furthermore, we have tested the in vitro and in vivo efficacy of DispersinB® wound spray in combination with nanocrystalline silver containing Acticoat™ wound dressing. DispersinB® is a naturally occurring enzyme produced by an oral bacterium Aggregatibacter actinomycetemcomitans, which is associated with juvenile periodontitis. 6 DispersinB® is active against poly-N-acetylglucosamine (PNAG), which is a major polysaccharide in biofilms of wound-associated bacteria such as Staphylococcus aureus, Staphylococcus epidermidis, Klebsiella pneumoniae, and Acinetobacter baumannii. It has been shown to inhibit biofilm formation and disperse preformed biofilm in these bacteria without exhibiting any antibacterial activity. 7 However, DispersinB® in combination with an antimicrobial has been shown to make the bacteria more susceptible to antimicrobial killing either by inhibiting biofilm formation or by disrupting preformed biofilm. 8, 9 Silver is an antimicrobial present in many wound care products and has a broad spectrum antimicrobial activity because of its interaction with sulfhydryl (-SH) groups of proteins as well as bases of DNA leading either to the inhibition of respiratory processes or DNA unwinding. 10, 11 The efficacy of silver-impregnated dressings for treatment of wounds has remained inconclusive with some meta-analyses supportive and some not. 12 Although silver has been demonstrated to be efficacious alone against biofilm growth, over the course of treatment, bacterial biofilms have exhibited a remarkable ability to overcome single-treatment antimicrobials. Indeed, silver resistance has been demonstrated in clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). 13 Therefore, development of a novel synergistic combination with an antibiofilm agent that enhances the efficacy of silver may have a significant therapeutic value.
Materials and Methods
Reagents, microorganisms, and culture conditions. All the chemicals (including media ingredients) were of analytical grade and purchased from Sigma-Aldrich (St. Louis, MO, USA) or BD Diagnostic Systems (Sparks, MD, USA). DispersinB® enzyme was purified from a recombinant Escherichia coli fermentation as previously described.
14, 15 The enzyme had a specific activity of ~10 3 units/mg of protein. 14, 15 DispersinB® wound spray comprising 200 µg mL -1 clinical grade DispersinB® in 50 mM sodium phosphate buffer containing 100 mM NaCl (pH 5.9) was formulated in a current good manufacturing practice (cGMP) facility, Therapure Biopharma Inc. (Mississauga, ON, Canada). The DispersinB® enzyme concentration in the wound spray was determined empirically. The commercial nanocrystalline silver containing wound dressing Acticoat™ was obtained from Smith and Nephew. The clinical wound isolates of S. epidermidis 1457, K. pneumoniae P30, and A. baumannii 63270 were provided by 3log 10 reduction in biofilm-embedded S. aureus compared to both control and Acticoat™ alone. In a chronic wound mouse model of MRSA infection, the combination of DispersinB® wound spray and Acticoat™ showed 80% reduction (P  0.05) in bioburden as compared to placebo treatment, and a moderate 14% reduction (P  0.05) when wounds were treated with Acticoat™ alone (Table 1) , indicating an increased antimicrobial activity of silver in combination with DispersinB®.
Discussion
It is well recognized that infections involving biofilms are difficult to eradicate, as sessile bacteria employ mechanisms that raise survival and resistance to antimicrobials up to 1000 times compared to their planktonic counterparts. 4 Wound treatment is primarily managed through mechanical manipulation such as debridement and choice of wound dressing. 5 Rationally designing wound dressings with effective antibiofilm control has the potential to significantly improve chronic wound therapy. The inhibition of biofilm formation and/or dispersal of preformed biofilms may make biofilmembedded bacteria more susceptible to antimicrobial therapy. DispersinB® wound spray showed broad spectrum biofilm inhibition and dispersal activity against wound-associated bacteria. Furthermore, we evaluated the effect of combining DispersinB® wound spray with Acticoat™ on wound-associated MRSA. DispersinB® wound spray in combination with Acticoat™ showed significantly (P  0.05) more reduction in biofilm-embedded MRSA compared to that by Acticoat™ alone, indicating the synergistic antibiofilm-antimicrobial activity of the combination. These findings are in agreement with previous reports describing the synergistic activity of the combination of antibiofilm enzyme DispersinB and antibiotics (cefamandole nafate or ampicillin) and non-antibiotic compounds such as triclosan. [7] [8] [9] The synergy between these two compounds could be attributed to DispersinB® making the bacteria embedded in biofilms more susceptible to antimicrobial Acticoat™ killing either by inhibiting biofilm formation or by disrupting preformed biofilms.
Furthermore, the efficacy of Acticoat™ and DispersinB® wound spray combination was studied in vivo using a chronic wound mouse model of MRSA infection. 17 DispersinB® wound spray enhanced the antimicrobial activity of Acticoat™ wound dressing. As two cysteines containing thiol groups present in the active site of C-terminal of DispersinB® were substituted with alanine, Acticoat™ did not affect the enzyme activity.
MRSA poses a major threat to hospital patients and accounts for 93.5% of venous leg ulcers-and 40% of diabetic foot ulcers-associated infections. 18 In addition, our previous study showed that silver containing wound gel ( Silver-Sept™) did not inhibit the growth of S. aureus, including methicillin-resistant as well as sensitive strains. 19 However, the DispersinB® wound spray and Acticoat™ combination showed a synergistic inhibitory effect on biofilm-embedded MRSA under both the in vitro and in vivo conditions. The other advantage of using antibiofilm and antimicrobial compounds in combinations with different modes of action is to minimize the probability of bacteria developing resistance. Treatment with a naturally occurring biocompatible DispersinB® enzyme 9 combined with a clinically safe Acticoat™ wound dressing could meet the unmet clinical need for biofilm-based chronic wound management. Thus, it would be prudent to evaluate the potential clinical application of this novel antibiofilm-antimicrobial combination for prevention and treatment of chronic wound-associated infections.
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